What dose of urolithin A do studies and the maker give?
| Form | Strength and daily amount |
|---|---|
| Maker's vegan softgels | Two softgels daily (500 mg), per the maker's page, which says the product is intended for healthy adults, ages 18 and up; 60 softgels per sachet5 |
| Trial softgels (Liu 2022, 66 older adults) | 250 mg each, four a day for 1000 mg1 |
| Japanese trial capsules (Nishimoto) | 10 mg or 50 mg a day4 |
How urolithin A is supplied
The table is set at the top of the page
The trials and the maker's page give urolithin A as softgels or capsules, and one bioavailability study (Singh, 100 people) gave a Mitopure powder containing 500 mg; a DailyMed search returned no label for urolithin A.6 The FDA's GRAS letter answers a notice on urolithin A as an ingredient in foods.7
Doses and schedules in human trials
| Trial | Daily dose and schedule | People | Length |
|---|---|---|---|
| ATLAS (Singh 2022) | 500 mg or 1,000 mg, or placebo3 | 88 (29 placebo, 29 at 500 mg, 30 at 1,000 mg)3 | 4 months3 |
| Older adults (Liu 2022) | 1000 mg as 4 softgels of 250 mg in the morning on an empty stomach with a glass of water, or placebo1 | 66 aged 65 to 90 (33 per arm)1 | 4 months1 |
| MitoImmune (Denk) | 1,000 mg as a daily single dose, at most four 250 mg softgels, or placebo8 | 50 healthy adults aged 45–708 | 28 days8 |
| Runners (Whitfield, NCT04783207) | 1000 mg·day−1, or placebo2 | 42 male runners (22 urolithin A, 20 placebo)2 | 4 weeks2 |
| Obesity (da Costa Pinaffi-Langley 2026) | 1000 mg a day as 2 doses of two 250-mg capsules, or control9 | 50 middle-aged adults with obesity (25 active, 25 control)9 | Mean follow-up 28 (2) days9 |
| Japanese (Nishimoto) | 10 mg or 50 mg a day in capsules, or placebo4 | UA non- or low-producers4 | 12 weeks4 |
| Heart failure (Jamialahmadi 2024) | 500 mg twice daily (BID) and placebo, in a crossover10 | 10 patients with heart failure with reduced ejection fraction10 | Two periods, 2-week washout10 |
The Andreux 2019 first-in-human trial gave urolithin A as a single dose or as multiple doses over 4 weeks to healthy, sedentary elderly people and reported, as secondary outcomes, that 4 weeks at 500 mg and 1,000 mg modulated plasma acylcarnitines and skeletal muscle mitochondrial gene expression; the saved text does not give its arm sizes, and a systematic review describes it as 250–1,000 mg/day for 28 days with single doses up to 2,000 mg.1112 A systematic review concluded that the available randomized human evidence is limited to five small, short-term trials in heterogeneous populations.12
Upper limits and the FDA letter
A search found no label maximum for urolithin A. The ATLAS trial (88 people) reported both doses as safe and well tolerated over 120 days.3 The notice behind the FDA GRAS letter is for urolithin A in protein shakes, meal replacement drinks, instant oatmeal, protein and nutrition bars, and yogurt drinks at up to 500 mg/serving, and in Greek yogurts, high protein yogurts, and milk-based protein shakes at up to 1000 mg/serving.7 It also reports the notifier's estimated dietary exposure for people 12 and older: a mean of 1,183 mg and a 90th percentile of 2,421 mg per person per day, an estimate and not a dose.7
Storage
The FDA letter relays the notifier's statement that urolithin A is stable for three years at room temperature, which concerns the ingredient and not a finding on supplements.7 The letter and the maker's page give no storage conditions for softgels or for any mixed form.
Frequently asked questions
How do you mix urolithin A powder?
No mixing instruction for powder with water turned up in the bioavailability study or on the maker's page.
Is there a syringe mark for urolithin A?
No: the trials and the maker's page give urolithin A by mouth, as softgels, capsules or a powder, and a search of DailyMed, PubMed and the trial registry found no injectable or liquid form with a concentration, so no U-100 syringe mark applies.
Is there a cycle for urolithin A?
No on and off schedule turned up in the FDA letter or the trials.
References
- PMC. Effect of Urolithin A Supplementation on Muscle Endurance and Mitochondrial Health in Older Adults. 2022. pmc.ncbi.nlm.nih.gov
- PMC. Evaluating the Impact of Urolithin A Supplementation on Running Performance, Recovery, and Mitochondrial Biomarkers in Highly Trained Male Distance Runners. 2025. pmc.ncbi.nlm.nih.gov
- PMC. Urolithin A improves muscle strength, exercise performance, and biomarkers of mitochondrial health in a randomized trial in middle-aged adults. 2022. pmc.ncbi.nlm.nih.gov
- Frontiers in Nutrition. Effect of urolithin A on the improvement of vascular endothelial function depends on the gut microbiota. 2023. pmc.ncbi.nlm.nih.gov
- Timeline. Mitopure Softgels. timeline.com
- PMC. Direct supplementation with Urolithin A overcomes limitations of dietary exposure and gut microbiome variability in healthy adults to achieve consistent levels across the population. 2021. pmc.ncbi.nlm.nih.gov
- FDA. Agency Response Letter GRAS Notice No. GRN 000791 - FDA has no questions. fda.gov
- PMC. Effect of the mitophagy inducer urolithin A on age-related immune decline: a randomized, placebo-controlled trial. 2025. pmc.ncbi.nlm.nih.gov
- PMC. Urolithin A and Endothelial and Cerebrovascular Function in Middle-Aged Adults With Obesity. 2026. pmc.ncbi.nlm.nih.gov
- PubMed. Evaluation of Urolithin A Efficacy in Heart Failure Patients with Reduced Ejection Fraction: A Randomized, Double-blind, Crossover, Placebo-controlled Clinical Trial. 2024. pubmed.ncbi.nlm.nih.gov
- Nature Metabolism. The mitophagy activator urolithin A is safe and induces a molecular signature of improved mitochondrial and cellular health in humans. nature.com
- PMC. Effects of Urolithin A supplementation on muscle health outcomes in humans from randomized controlled trials. 2026. pmc.ncbi.nlm.nih.gov